ZA200807600B - Pharmaceutical composition containing GHRP-6 capable of preventing and elimanting fibrosis and other forms of pathological deposit in tissue - Google Patents

Pharmaceutical composition containing GHRP-6 capable of preventing and elimanting fibrosis and other forms of pathological deposit in tissue

Info

Publication number
ZA200807600B
ZA200807600B ZA200807600A ZA200807600A ZA200807600B ZA 200807600 B ZA200807600 B ZA 200807600B ZA 200807600 A ZA200807600 A ZA 200807600A ZA 200807600 A ZA200807600 A ZA 200807600A ZA 200807600 B ZA200807600 B ZA 200807600B
Authority
ZA
South Africa
Prior art keywords
elimanting
fibrosis
tissue
preventing
forms
Prior art date
Application number
ZA200807600A
Other languages
English (en)
Inventor
Berlanga Acosta Jorge
Cibrian Vera Danay
Garcia Del Barco Herrera Diana
Guillen Nieto Gerardo Enrique
Suarez Alba Jose
Lopez Mola Ernesto
Selman-Housein Sosa Manuel
Vazquez Castillo Mariela
Original Assignee
Ct L De Ingenieria Genetica Y
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct L De Ingenieria Genetica Y filed Critical Ct L De Ingenieria Genetica Y
Publication of ZA200807600B publication Critical patent/ZA200807600B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ZA200807600A 2006-02-28 2008-09-03 Pharmaceutical composition containing GHRP-6 capable of preventing and elimanting fibrosis and other forms of pathological deposit in tissue ZA200807600B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060048A CU23592A1 (es) 2006-02-28 2006-02-28 Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6

Publications (1)

Publication Number Publication Date
ZA200807600B true ZA200807600B (en) 2009-06-24

Family

ID=37964643

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200807600A ZA200807600B (en) 2006-02-28 2008-09-03 Pharmaceutical composition containing GHRP-6 capable of preventing and elimanting fibrosis and other forms of pathological deposit in tissue

Country Status (16)

Country Link
US (2) US20090221512A1 (fr)
EP (2) EP2368563A1 (fr)
JP (1) JP5426175B2 (fr)
KR (1) KR101462077B1 (fr)
CN (1) CN101426517B (fr)
AR (1) AR059644A1 (fr)
AU (1) AU2007219568B2 (fr)
BR (1) BRPI0708349B8 (fr)
CA (1) CA2644431C (fr)
CU (1) CU23592A1 (fr)
DK (1) DK1994939T3 (fr)
ES (1) ES2388879T3 (fr)
MX (1) MX2008011140A (fr)
RU (1) RU2465913C2 (fr)
WO (1) WO2007098715A1 (fr)
ZA (1) ZA200807600B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121767A2 (fr) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Polypeptides cousus
WO2012021876A2 (fr) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR101667383B1 (ko) * 2012-03-28 2016-10-18 주식회사 인코스팜 비오틴이 결합된 hexapeptide-2 유도체 및 이의 용도
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
KR102051433B1 (ko) * 2013-08-27 2020-01-08 (주)네오팜 근육 분화 촉진 및 근육 강화용 조성물 및 외용제
US9119832B2 (en) * 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2016049359A1 (fr) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
FR3034662B1 (fr) * 2015-04-10 2020-08-28 Isp Investments Inc Nouvelles utilisations du peptide de sequence his-d-trp-ala-trp-d-phe-lys-nh2 pour diminuer ou retarder l'apparition de la senescence cellulaire et des signes du vieillissement cutane
CN106730414B (zh) * 2015-12-30 2017-10-10 南京中硼联康医疗科技有限公司 用于消除β淀粉样蛋白的中子捕获治疗系统
CN109908331A (zh) * 2019-04-30 2019-06-21 青岛大学附属医院 海沙瑞林在制备保护肾脏缺血再灌注损伤药物/药物组合物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
DE60022683D1 (de) * 1999-12-28 2005-10-20 Kaken Pharma Co Ltd Nervenschutzmittel
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
AU2002349485A1 (en) * 2001-12-07 2003-06-17 Kaken Pharmaceutical Co., Ltd. Cell migration inhibitor
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
AU2004233705C1 (en) * 2003-04-30 2010-04-01 Kenji Kangawa Preventives or remedies for hepatopathy
JP2005239712A (ja) * 2004-01-30 2005-09-08 Kaken Pharmaceut Co Ltd 神経突起伸展剤
WO2005112903A2 (fr) * 2004-05-14 2005-12-01 Novo Nordisk A/S Utilisation d'antagonistes de la ghrelin pour le traitement de certaines maladies du systeme nerveux central

Also Published As

Publication number Publication date
EP1994939A1 (fr) 2008-11-26
KR101462077B1 (ko) 2014-11-20
KR20080100378A (ko) 2008-11-17
BRPI0708349A2 (pt) 2011-05-24
US8722626B2 (en) 2014-05-13
RU2465913C2 (ru) 2012-11-10
RU2008138561A (ru) 2010-04-10
JP5426175B2 (ja) 2014-02-26
DK1994939T3 (da) 2012-09-10
US20110230415A1 (en) 2011-09-22
CU23592A1 (es) 2010-11-11
CA2644431C (fr) 2016-08-30
AR059644A1 (es) 2008-04-16
MX2008011140A (es) 2008-09-08
AU2007219568A1 (en) 2007-09-07
JP2009528302A (ja) 2009-08-06
US20090221512A1 (en) 2009-09-03
AU2007219568B2 (en) 2012-10-04
EP2368563A1 (fr) 2011-09-28
BRPI0708349B8 (pt) 2021-05-25
ES2388879T3 (es) 2012-10-19
WO2007098715A1 (fr) 2007-09-07
CA2644431A1 (fr) 2007-09-07
CN101426517A (zh) 2009-05-06
EP1994939B1 (fr) 2012-05-30
CN101426517B (zh) 2013-04-03
BRPI0708349B1 (pt) 2019-04-24

Similar Documents

Publication Publication Date Title
ZA200807600B (en) Pharmaceutical composition containing GHRP-6 capable of preventing and elimanting fibrosis and other forms of pathological deposit in tissue
HUS1900038I1 (hu) Nátrium-glükóz kotranszporter-2 inhibitorai és alkalmazási eljárásaik
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
IL197275A0 (en) Pharmaceutical compositions of clonazepam and methods of use thereof
IL244761A0 (en) Film-coated and/or granulated calcium-containing compounds and their use in medical preparations
EP1765379A4 (fr) Compositions pharmaceutiques de co-cristal et methodes d'utilisation associees
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
IL191604A0 (en) Pharmaceutical compositions containing mixtures of polymers and active agents poorly soluble in water
EP1973986A4 (fr) Compositions bioactives complexes et leurs méthodes d'utilisation
EP2064550A4 (fr) Compositions associees a prrg4 et procedes d'utilisation de celles-ci dans des procedes de diagnostic de tumeur
IL184735A0 (en) Pharmaceutical formulations and methods of use
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
HK1112427A1 (en) Drug delivery compositions and related methods
EP1862183A4 (fr) Composition pharmaceutique contenant un médicament à peine soluble dans l'eau
EP1930001A4 (fr) Produit pharmaceutique à utiliser dans la prévention et/ou le traitement d'affections abdominales
IL197273A0 (en) Pharmaceutical and sunscreen compositions comprising caspase-14
EP2051721A4 (fr) Préparation et utilisation pharmaceutique de compositions à base d'extrait d'euterpe oleracea (acai)
ZA200900416B (en) Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
GB0614365D0 (en) Pharmaceutical compositions and their use
EP1970078A4 (fr) Composition inhibant l'expression d'un gene cible du globe oculaire et remede pour une maladie du globe oculaire
EP2121596A4 (fr) Sel d'atarvastatine-strontium et composition pharmaceutique le contenant
PL375008A1 (pl) Nowe zastosowanie medyczne chlorowodorku epirubicyny
IL189827A0 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
ZA200609585B (en) Compositions comprising glycosaminoglycan and non steriodal anti-inflammatory drug
IL177751A0 (en) Pharmaceutical composition of (+)-erythro-mefloquine and its use